Literature DB >> 21095461

The chemistry of catechol-O-methyltransferase inhibitors.

David A Learmonth1, László E Kiss, Patrício Soares-da-Silva.   

Abstract

Despite several drawbacks, levodopa (L-dopa) remains the gold standard drug for treatment of the symptoms of Parkinson's disease (PD). L-dopa is a pro-drug of dopamine and is used to elevate striatal levels of the neurotransmitter. One approach to provide a more continuous and sustained delivery of dopamine has targeted one of the principal enzymes responsible for metabolic deactivation of L-dopa, namely catechol-O-methyltransferase (COMT). The chapter will provide a perspective of the medicinal chemistry behind the discovery of several COMT inhibitors and discuss how certain physicochemical parameters, including aqueous solubility and lipophilicity, are thought to influence pharmacokinetic properties such as absorption, distribution, and bioavailability.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21095461     DOI: 10.1016/B978-0-12-381326-8.00006-5

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  5 in total

1.  Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT).

Authors:  Scott T Harrison; Michael S Poslusney; James J Mulhearn; Zhijian Zhao; Nathan R Kett; Jeffrey W Schubert; Jeffrey Y Melamed; Timothy J Allison; Sangita B Patel; John M Sanders; Sujata Sharma; Robert F Smith; Dawn L Hall; Ronald G Robinson; Nancy A Sachs; Pete H Hutson; Scott E Wolkenberg; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2015-01-26       Impact factor: 4.345

2.  Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.

Authors:  Ingrid Buchler; Daniel Akuma; Vinh Au; Gregory Carr; Pablo de León; Michael DePasquale; Glen Ernst; Yifang Huang; Martha Kimos; Anna Kolobova; Michael Poslusney; Huijun Wei; Dominique Swinnen; Florian Montel; Florence Moureau; Emilie Jigorel; Monika-Sarah E D Schulze; Martyn Wood; James C Barrow
Journal:  J Med Chem       Date:  2018-10-19       Impact factor: 7.446

3.  Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.

Authors:  Luis Almeida; José Francisco Rocha; Amílcar Falcão; P Nuno Palma; Ana I Loureiro; Roberto Pinto; Maria João Bonifácio; Lyndon C Wright; Teresa Nunes; Patrício Soares-da-Silva
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 4.  The structural biology of oestrogen metabolism.

Authors:  Mark P Thomas; Barry V L Potter
Journal:  J Steroid Biochem Mol Biol       Date:  2013-01-04       Impact factor: 4.292

5.  Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol O-Methyltransferase.

Authors:  Glen Ernst; Daniel Akuma; Vinh Au; Ingrid P Buchler; Spencer Byers; Gregory V Carr; Sabine Defays; Pablo de León; Thierry Demaude; Michael DePasquale; Véronique Durieu; Yifang Huang; Emilie Jigorel; Martha Kimos; Anna Kolobova; Florian Montel; Florence Moureau; Michael Poslusney; Dominique Swinnen; Marie-Christine Vandergeten; Nathalie Van Houtvin; Huijun Wei; Noelle White; Martyn Wood; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2019-10-22       Impact factor: 4.345

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.